Vivani Medical, Inc. (NASDAQ:VANI) Sees Significant Decrease in Short Interest

Vivani Medical, Inc. (NASDAQ:VANI) was the recipient of a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 290,597 shares, a decrease of 25.4% from the February 12th total of 389,363 shares. Based on an average daily volume of 201,565 shares, the days-to-cover ratio is currently 1.4 days. Approximately 0.7% of the company’s shares are sold short. Approximately 0.7% of the company’s shares are sold short. Based on an average daily volume of 201,565 shares, the days-to-cover ratio is currently 1.4 days.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on VANI shares. Wall Street Zen raised shares of Vivani Medical to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Vivani Medical presently has an average rating of “Hold” and a consensus target price of $4.00.

Vivani Medical Stock Down 0.9%

Shares of VANI stock opened at $1.10 on Friday. The stock has a market capitalization of $85.99 million, a PE ratio of -2.44 and a beta of 3.17. The stock’s 50-day moving average price is $1.28 and its 200 day moving average price is $1.36. Vivani Medical has a 52-week low of $0.91 and a 52-week high of $1.92.

Insider Buying and Selling at Vivani Medical

In other Vivani Medical news, Director Gregg Williams purchased 1,351,351 shares of the stock in a transaction dated Tuesday, January 27th. The stock was acquired at an average cost of $1.48 per share, for a total transaction of $1,999,999.48. Following the acquisition, the director owned 27,915,460 shares in the company, valued at $41,314,880.80. This trade represents a 5.09% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have purchased 4,826,881 shares of company stock valued at $5,962,104. Corporate insiders own 46.40% of the company’s stock.

Hedge Funds Weigh In On Vivani Medical

Large investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in shares of Vivani Medical during the 3rd quarter worth $26,000. Panagora Asset Management Inc. purchased a new position in shares of Vivani Medical in the second quarter valued at $25,000. Susquehanna International Group LLP increased its position in shares of Vivani Medical by 100.5% in the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after buying an additional 16,200 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Vivani Medical during the 4th quarter worth $60,000. Finally, Renaissance Technologies LLC boosted its position in shares of Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after buying an additional 53,127 shares in the last quarter. 6.78% of the stock is owned by hedge funds and other institutional investors.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.